Last reviewed · How we verify
LPCN 1154A
LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues.
LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues. Used for Testosterone replacement therapy in hypogonadal men.
At a glance
| Generic name | LPCN 1154A |
|---|---|
| Also known as | Brexanolone |
| Sponsor | Lipocine Inc. |
| Drug class | Androgen receptor modulator |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | Phase 3 |
Mechanism of action
LPCN 1154A is designed to provide selective androgen receptor activation with tissue-specific effects, potentially offering therapeutic benefits in conditions requiring androgen replacement or androgen-dependent processes while minimizing systemic androgenic side effects. The drug is being developed as an oral formulation to improve patient compliance compared to injectable testosterone therapies.
Approved indications
- Testosterone replacement therapy in hypogonadal men
Common side effects
- Polycythemia
- Prostate-related adverse events
- Lipid profile changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |